{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:12:19Z","timestamp":1792001539170,"version":"4.4.0"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T00:00:00Z","timestamp":1561852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent phase 3 clinical trials have evaluated the impact of adding sodium\u2010glucose co\u2010transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non\u2010insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the risk of DKA and still gain the multiple benefits, we developed the \u201cSTOP DKA Protocol \u201c, an easily accessible and practical tool, that provides a risk mitigation strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.<\/jats:p>","DOI":"10.1111\/dom.13811","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T02:18:31Z","timestamp":1560219511000},"page":"2192-2202","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Sodium\u2010glucose co\u2010transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-3255","authenticated-orcid":false,"given":"Ronald M.","family":"Goldenberg","sequence":"first","affiliation":[{"name":"LMC Diabetes and Endocrinology  Concord Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Hramiak","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, St Joseph's Health Care London, Schulich School of Medicine and Dentistry Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Woo","sequence":"additional","affiliation":[{"name":"Section of Endocrinology and Metabolism, Health Sciences Centre University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0041-1876","authenticated-orcid":false,"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[{"name":"Lunenfeld\u2010Tanenbaum Research Institute, Mt Sinai Hospital University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,30]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"22","article-title":"Epidemiology of diabetes","volume":"47","author":"Forouhi NG","year":"2018","journal-title":"Medicine (Abingdon)"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4763-3"},{"key":"e_1_2_10_4_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2017"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0384"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1689-P"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6712a3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1160"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1583"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1084"},{"key":"e_1_2_10_11_1","first-page":"210","article-title":"The incidence and impact of hypoglycemia in type 1 and type 2 diabetes","volume":"21","author":"Frier B","year":"2009","journal-title":"Int Diabetes Monitor"},{"key":"e_1_2_10_12_1","first-page":"26","article-title":"Drugs for diabetes: part 8 SGLT2 inhibitors","volume":"19","author":"MacEwen A","year":"2012","journal-title":"Br J Cardiol"},{"key":"e_1_2_10_13_1","volume-title":"Forxiga Approved in Japan for Type\u20101 Diabetes","author":"Kemp A","year":"2019"},{"key":"e_1_2_10_14_1","volume-title":"Forxiga Approved in Europe for Type\u20101 Diabetes","author":"Kemp A","year":"2019"},{"key":"e_1_2_10_15_1","volume-title":"ZynquistaTM Now Approved in the European Union for Treatment of Adults with Type 1 Diabetes","author":"Sanofi, Lexicon Pharmaceuticals","year":"2019"},{"key":"e_1_2_10_16_1","volume-title":"FDA Turns Down Sotagliflozin for Type 1 Diabetes","author":"Tucker ME","year":"2019"},{"issue":"1","key":"e_1_2_10_17_1","first-page":"S109","article-title":"Hyperglycemic emergencies in adults","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","journal-title":"Can J Diabetes"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.17925\/USE.2017.13.02.75"},{"key":"e_1_2_10_20_1","volume-title":"Clinical Guiding Principles for Sick Day Management of Adults with Type 1 and Type 2 Diabetes","author":"Australian Diabetes Educators Association","year":"2016"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12741"},{"key":"e_1_2_10_22_1","volume-title":"Insulin Sick Day Management for Diabetes (Non\u2010DKA) Pathway","author":"Seattle Children's Hospital","year":"2013"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1087"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0623"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1749"},{"key":"e_1_2_10_27_1","unstructured":"GremplerR ThomasL EckhardtM et al in vitro properties and in vivo effect on urinary glucose excretion of BI 10773 a novel selective SGLT2 inhibitor. Paper presented at: 69th Scientific Sessions of the American Diabetes Association;2009; New Orleans LA."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1472"},{"key":"e_1_2_10_29_1","unstructured":"LiangY ArakawaK MartinT et al JNJ\u201028431754\/TA\u20107284 an SGLT inhibitor lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models. Paper presented at: 69th Scientific Sessions of the American Diabetes Association;2009; New Orleans LA."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.58"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00286.2014"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00518.2013"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0343"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0342"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"e_1_2_10_36_1","unstructured":"Astellas Pharma Inc. Kotobuki Pharmaceutical Co. Ltd. Approval of Suglat\u00ae tablets selective SGLT2 inhibitor for additional Indication of type 1 diabetes mellitus and additional dosage and administration in Japan.https:\/\/www.astellas.com\/en\/news\/14481. Accessed February 25 2019."},{"key":"e_1_2_10_37_1","volume-title":"First Oral Add\u2010on Treatment to Insulin for Treatment of Certain Patients with Type 1 Diabetes. Committee for Medicinal Products for Human Use (CHMP)","author":"European Medicines Agency","year":"2019"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0246"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2316"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.934.454"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0186"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2016.13.217"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13811","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:40Z","timestamp":1761871480000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,30]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/dom.13811"],"URL":"https:\/\/doi.org\/10.1111\/dom.13811","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,30]]},"assertion":[{"value":"2019-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}